Document is current
Any future updates will be listed below
-
Authors
Tempest-Roe, Shenzhen https://orcid.org/0000-0001-9043-8337
Prendecki, Maria
McAdoo, Stephen P.
Clarke, Candice
Tanna, Anisha
Turner-Stokes, Tabitha
Masuda, Esteban S.
Willicombe, Michelle
Cook, H. Terence
Roufosse, Candice
Taube, David
Pusey, Charles D.
Tam, Frederick W. K.
-
Funding
Funding for this research was provided by:
Kidney Research UK (Making Every Kidney Count)
Imperial College Charity Fund
- License Information
-
More Information
Article History
Received: 19 June 2021
Accepted: 17 November 2021
First Online: 28 February 2022
Competing interests
: FWKT has received research project grants from AstraZeneca Limited, Baxter Biosciences, Boehringer Ingelheim, MedImmune and Rigel Pharmaceuticals, and has consultancy agreements with Rigel Pharmaceuticals, Novartis and Baxter Biosciences, and is the Chief Investigator of an international clinical trial of a SYK inhibitor in IgA nephropathy (ClinicalTrials.gov NCT02112838) funded by Rigel Pharmaceuticals and a phase 2 clinical trial of fostamatinib in the treatment of chronic active antibody mediated rejection in renal transplantation, funded by Rigel Pharmaceuticals and Auchi Charitable Fund (EudraCT Number: 2018-000027-14). CDP has received a research project grant from GlaxoSmithKline and has a consultancy agreement with Genzyme. EM owns stock and is employed by Rigel Pharmaceuticals, Inc. CR reports personal fees from UCB, personal fees from Achillion Pharmaceutical, personal fees from Rigel Pharmaceuticals outside the submitted work. All other authors do not have competing interests.
